Anthem Biosciences Ltd (ANTHEM) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 544449 | NSE: ANTHEM | Pharmaceuticals & Drugs | Mid Cap

Anthem Biosciences Share Price

652.70 -8.80 -1.33%
as on 05-Dec'25 12:17

Anthem Biosciences Ltd (ANTHEM) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 544449 | NSE: ANTHEM | Pharmaceuticals & Drugs | Mid Cap

DeciZen - make an informed investing decision on Anthem Biosciences

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Anthem Biosciences stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
73.39
Market Cap:
37,150.5 Cr.
52-wk low:
620.1
52-wk high:
873.3

Is Anthem Biosciences Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Anthem Biosciences: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Anthem Biosciences Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 32.3%29.4%17.2%25.9%25.6%55.4%50.8%31.2%25%30.8%-
Value Creation
Index
1.91.60.51.31.33.93.51.81.21.2-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 2093574626266331,1031,2311,0571,4181,8411,841
Sales YoY Gr.-70.5%29.6%35.5%1.1%74.4%11.6%-14.2%34.1%29.9%-
Adj EPS 0.71.20.61.41.64.7766.599
YoY Gr.-59.7%-51.3%141.1%20.7%189.6%47.5%-14.5%9.9%37.2%-
BVPS (₹) 2.244.66.17.812.723.830.534.643.650.8
Adj Net
Profit
39.162.730.573.488.5260397339366501506
Cash Flow from Ops. 000196166278333319164440-
Debt/CF from Ops. 000110.40.10.410.3-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 27.3%23.8%14.3%29.9%
Adj EPS 32.4%40.6%8.8%37.2%
BVPS39.2%41.3%22.5%26.1%
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
38.536.812.82523.546.338.621.919.922.819.1
Op. Profit
Mgn %
35.430.526.227.428.83745.940.835.737.538.1
Net Profit
Mgn %
18.717.66.611.71423.632.232.125.827.227.5
Debt to
Equity
0.90.910.60.40.100.10.100
Working Cap
Days
16514817116417211413219822725485
Cash Conv.
Cycle
737388798754679811011668

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Anthem Biosciences Ltd.

Standalone Consolidated
TTM EPS (₹) 9 8
TTM Sales (₹ Cr.) 1,841 1,845
BVPS (₹.) 50.8 49
Reserves (₹ Cr.) 2,741 2,640
P/BV 13.02 13.50
PE 73.39 82.33
From the Market
52 Week Low / High (₹) 620.05 / 873.25
All Time Low / High (₹) 620.05 / 873.25
Market Cap (₹ Cr.) 37,151
Equity (₹ Cr.) 112.3
Face Value (₹) 2
Industry PE 40.7

Management X-Ray of Anthem Biosciences:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Anthem Biosciences - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Anthem Biosciences

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales2093574626266331,1031,2311,0571,4181,841
Operating Expenses 1352483414544516966666349131,151
Manufacturing Costs192836424954778680101
Material Costs64136195275252454414339600741
Employee Cost 316382107120142138153183252
Other Costs 21212829304538565057
Operating Profit 74109121172182408565423505689
Operating Profit Margin (%) 35.4%30.5%26.2%27.4%28.8%37.0%45.9%40.0%35.6%37.4%
Other Income 4610212137498571109
Interest 451818201710999
Depreciation 18225361626258648178
Exceptional Items 00000006200
Profit Before Tax 568860114121366547498485711
Tax 152225372894141112110205
Profit After Tax 4166367793271406386375506
PAT Margin (%) 19.4%18.6%7.8%12.3%14.7%24.6%33.0%36.5%26.4%27.5%
Adjusted EPS (₹)0.81.20.71.41.74.97.16.86.79.1
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 1212192553314227011,3551,7421,9332,439
Share Capital 811118889114112112
Reserves 1132092443234136931,3471,6281,8212,327
Minority Interest0000000000
Debt10419124116012110035114167109
Long Term Debt7715617113795206856647
Short Term Debt273569232680302910162
Trade Payables1533575458616572100110
Others Liabilities 506053166175157148156203318
Total Liabilities 2915046067117761,0201,6032,0832,4032,976

Fixed Assets

Gross Block1303404645165676827078849911,210
Accumulated Depreciation6187140201261321378435513586
Net Fixed Assets 69252324316306361329449478624
CWIP 7544712501915314315658
Investments 242777399209273499472533
Inventories305883921253558129211339
Trade Receivables4974122117105255326274490448
Cash Equivalents 4115142241349343184311
Others Assets 4038608969100115245412664
Total Assets 2915046067117761,0201,6032,0832,4032,976

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 000196166278333319164440
PBT 000114121366547498485711
Adjustment 00077767748273736
Changes in Working Capital 000514-94-138-91-238-149
Tax Paid 0000-45-71-123-115-120-159
Cash Flow From Investing Activity 000-121-109-196-206-378-192-246
Capex 000-52-51-118-89-184-111-225
Net Investments 000-66-24-111-1-22627-61
Others 000-3-3433-11532-10840
Cash Flow From Financing Activity 000-65-48-6318153-132-66
Net Proceeds from Shares 0000082477900
Net Proceeds from Borrowing 000-49-40-60-14-18-19-19
Interest Paid 000-18-20-17-10-1-9-8
Dividend Paid 00000-0-0000
Others 0001126-43-7-103-39
Net Cash Flow 0009918308-6-159127

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)40.0239.1115.2426.3924.6248.339.4824.9120.423.16
ROCE (%)32.2929.4217.2425.8725.5655.3650.7831.224.9830.79
Asset Turnover Ratio0.880.90.830.950.851.230.940.570.630.68
PAT to CFO Conversion(x)0002.551.781.030.820.830.440.87
Working Capital Days
Receivable Days716377706460861049893
Inventory Days43455651632714324455
Payable Days91668573814855745252

Anthem Biosciences Ltd Stock News

Anthem Biosciences Ltd FAQs

The current trading price of Anthem Biosciences on 05-Dec-2025 12:17 is ₹652.7.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Anthem Biosciences stood at ₹37,150.5.
The latest P/E ratio of Anthem Biosciences as of 04-Dec-2025 is 73.39.
The latest P/B ratio of Anthem Biosciences as of 04-Dec-2025 is 13.02.
The 52-week high of Anthem Biosciences is ₹873.2 and the 52-week low is ₹620.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Anthem Biosciences is ₹1,841 ( Cr.) .

About Anthem Biosciences Ltd

Anthem Biosciences Limited was originally incorporated as ‘Anthem Biosciences Private Limited’ under the provisions of the Companies Act, 1956, pursuant to a certificate of incorporation dated June 13, 2006, issued by RoC. Subsequently, the company was converted from a private company to a public company, pursuant to a board resolution dated October 18, 2024 and a resolution passed in the extraordinary general meeting of its Shareholders held on October 18, 2024 following which the name of the company was changed to ‘Anthem Biosciences Limited’ and a certificate of incorporation consequent upon conversion to public limited company was issued by the RoC on December 10, 2024.

The company is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities across drug discovery, development, and commercial manufacturing. It provides end to end CRDMO services and it serves a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally. 

Its CRDMO platform comprises main modalities (RNAi, ADC, peptides, lipids and oligonucleotides) and manufacturing capabilities (custom synthesis, flow chemistry, fermentation and biotransformation). It derives revenue primarily from its CRDMO services, including developmental and commercial manufacturing, and research and development services. It also generates revenue from the manufacture and sale of specialty ingredients.

Business area of the company

Anthem Biosciences has been set up as a Life sciences/ Biotechnology based venture specialising in the manufacture of catalytic preparation, other organic compounds such as speciality organic molecules, biologically active peptides etc., which are high-value products used in drug, agrochemical and speciality chemicals industries. 

Awards, accreditations, and recognition

  • 2023: Received a certificate of recognition as a ‘Four Star Export House’ from the Ministry of Commerce and Industry.
  • 2023: Received an accreditation from AAALAC International.
  • 2023: Received the Bureau Veritas Certification for achieving the ISO 9001:2015, ISO 14001:2015 & ISO 45001:2018 standards.
  • 2024: Received the certification as a foreign drug manufacturer issued by the Minister of Health, Labour and Welfare.
  • 2024: Received the ‘Pharma Excellence Award’ for excellence in contribution towards sustainability issued by ASSOCHAM.
  • 2025: Received a certificate of appreciation in recognition of appreciable achievement in occupation safety and health during 2021-2023 from the National Safety Council of India Safety Awards - 2024.
  • 2025: Received the State Level safety award under the category of Best Large Scale Industry.

History and milestones

  • 2006: Incorporation of the company.
  • 2007: Commenced operations of the company at Unit I and set up a custom synthesis plant with a capacity of 6 KL.
  • 2008: Commencement of the discovery biology services with a fermentation capacity of 2 KL.
  • 2010: Expanded the custom synthesis plant set up at Unit I increasing its capacity from 6 KL to 24 KL.
  • 2013: Received the first USFDA audit approval for Unit I.
  • 2016: Set up a high potent lab at Unit I - Bommasandra Facility.
  • 2017: The company, pursuant to an order dated November 30, 2017, amalgamated with Anthem Cellutions (India) Private Limited by way of an acquisition of 100% of its share capital.
  • 2017: Set up a solid phase peptide synthesis GMP lab with a capacity of 6 KL at Unit 1.
  • 2017: Commenced operations of the Company at Unit II and set up an automated GMP compliant custom synthesis plant with a capacity of 128 KL and a fermentation plant with a capacity of 80 KL.
  • 2017: Received the second USFDA audit approval for Unit I.
  • 2018: Anthem Cellutions (India) Private Limited amalgamated into the company.
  • 2019: Received the third USFDA approval for Unit I.
  • 2019: Set up a flow chemistry lab at Unit I.
  • 2020: Commenced operations in biological facility 2 earmarked for a specific client.
  • 2022: Expanded the custom synthesis plant set up at Unit II increasing its capacity to 246 KL.
  • 2023: Received the first USFDA audit approval and first therapeutic goods administration audit for Unit II.
  • 2023: Addition of Oligonucleotide lab in Unit I.
  • 2023: Set a cGMP scale continuous flow manufacturing facility for Unit II.
  • 2024: Received the: second USFDA audit approval for Unit II; first ANVISA audit approval for Unit I; and first ANVISA audit approval for Unit II.
  • 2024: Commenced operations of Neoanthem Lifesciences Private Limited, at Unit III designed as a chemistry lab and customer synthesis pilot plant for development, technology transfer and scale-up projects.
  • 2024: Fermentation capacity expanded to 140 KL at Unit II.
  • 2024: Conversion of the Company into a public limited company, under the name ‘Anthem Biosciences Limited’.
  • 2025: Received the fourth USFDA approval for Unit I.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×